127 related articles for article (PubMed ID: 25569856)
1. The Relationship of the Fibrinogen Cleavage Biomarker Aα-Val360 With Disease Severity and Activity in α1-Antitrypsin Deficiency.
Carter RI; Ungurs MJ; Pillai A; Mumford RA; Stockley RA
Chest; 2015 Aug; 148(2):382-388. PubMed ID: 25569856
[TBL] [Abstract][Full Text] [Related]
2. The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivo.
Carter RI; Mumford RA; Treonze KM; Finke PE; Davies P; Si Q; Humes JL; Dirksen A; Piitulainen E; Ahmad A; Stockley RA
Thorax; 2011 Aug; 66(8):686-91. PubMed ID: 21617168
[TBL] [Abstract][Full Text] [Related]
3. Aα-Val360: a marker of neutrophil elastase and COPD disease activity.
Carter RI; Ungurs MJ; Mumford RA; Stockley RA
Eur Respir J; 2013 Jan; 41(1):31-8. PubMed ID: 22523359
[TBL] [Abstract][Full Text] [Related]
4. Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography.
Subramanian DR; Jenkins L; Edgar R; Quraishi N; Stockley RA; Parr DG
Am J Respir Crit Care Med; 2012 Dec; 186(11):1125-32. PubMed ID: 22837375
[TBL] [Abstract][Full Text] [Related]
5. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
6. Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency.
Mostafavi B; Diaz S; Piitulainen E; Stoel BC; Wollmer P; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2018; 13():3689-3698. PubMed ID: 30510411
[TBL] [Abstract][Full Text] [Related]
7. CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency.
Holme J; Stockley RA
Chest; 2009 Nov; 136(5):1284-1290. PubMed ID: 19892672
[TBL] [Abstract][Full Text] [Related]
8. A specific proteinase 3 activity footprint in α
Newby PR; Crossley D; Crisford H; Stockley JA; Mumford RA; Carter RI; Bolton CE; Hopkinson NS; Mahadeva R; Steiner MC; Wilkinson TMA; Sapey E; Stockley RA
ERJ Open Res; 2019 Jul; 5(3):. PubMed ID: 31403052
[TBL] [Abstract][Full Text] [Related]
9. Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from alpha1-antitrypsin deficiency.
Holme J; Stockley RA
Chest; 2007 Sep; 132(3):909-15. PubMed ID: 17573491
[TBL] [Abstract][Full Text] [Related]
10. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in Alpha-1 Antitrypsin Deficiency Chronic Obstructive Pulmonary Disease.
Turino GM; Ma S; Cantor JO; Lin YY
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S336-40. PubMed ID: 27564670
[TBL] [Abstract][Full Text] [Related]
12. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
[TBL] [Abstract][Full Text] [Related]
13. Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol.
Strange C; Senior RM; Sciurba F; O'Neal S; Morris A; Wisniewski SR; Bowler R; Hochheiser HS; Becich MJ; Zhang Y; Leader JK; Methé BA; Kaminski N; Sandhaus RA;
Ann Am Thorac Soc; 2015 Oct; 12(10):1551-60. PubMed ID: 26153726
[TBL] [Abstract][Full Text] [Related]
14. Lung density associates with survival in alpha 1 antitrypsin deficient patients.
Green CE; Parr DG; Edgar RG; Stockley RA; Turner AM
Respir Med; 2016 Mar; 112():81-7. PubMed ID: 26874894
[TBL] [Abstract][Full Text] [Related]
15. Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age.
Piitulainen E; Montero LC; Nystedt-Düzakin M; Stoel BC; Sveger T; Wollmer P; Tanash HA; Diaz S
COPD; 2015 Apr; 12(2):162-7. PubMed ID: 25280185
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency.
Manca S; Rodriguez E; Huerta A; Torres M; Lazaro L; Curi S; Pirina P; Miravitlles M
COPD; 2014 Sep; 11(5):480-8. PubMed ID: 24832005
[TBL] [Abstract][Full Text] [Related]
17. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.
O'Brien ME; Pennycooke K; Carroll TP; Shum J; Fee LT; O'Connor C; Logan PM; Reeves EP; McElvaney NG
COPD; 2015 May; 12 Suppl 1():2-9. PubMed ID: 25938284
[TBL] [Abstract][Full Text] [Related]
18. The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency.
Campos MA; Diaz AA
Chest; 2018 May; 153(5):1240-1248. PubMed ID: 29175361
[TBL] [Abstract][Full Text] [Related]
19. The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency.
Banga A; Gildea T; Rajeswaran J; Rokadia H; Blackstone EH; Stoller JK
Am J Respir Crit Care Med; 2014 Aug; 190(3):274-81. PubMed ID: 25003824
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and radiological outcomes of lung nodules in alpha 1-antitrypsin deficiency.
Subramanian DR; Edgar R; Ward H; Parr DG; Stockley RA
Respir Med; 2013 Jun; 107(6):863-9. PubMed ID: 23337299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
